TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9287258
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASA 25 mg b.d. and dipyridamole 200 mg b.d.
Study: 8345978
Drug: Oral amoxicillin/potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/potassium clavulanate
Study: 3013567
Drug: Parenteral sulbactam/ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral sulbactam/ampicillin
Study: 31594205
Drug: Intra-articular distension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular distension followed by physical therapy (Group A)
Study: 31594205
Drug: Intra-articular distension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular distension preceded by physical therapy (Group B)
Study: 31594205
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone (Group C)
Study: 27181179
Drug: EPO (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (40,000 IU/ml)
Study: 25539560
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy before arthroscopic subacromial decompression
Study: 25539560
Drug: No conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No conservative therapy before arthroscopic subacromial decompression
Study: 25539560
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy before surgery
Study: 25539560
Drug: No conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No conservative therapy before surgery
Study: 15805993
Drug: Fluticasone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (200 microg twice daily for 1 week)
Study: 15805993
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 microg twice daily for 1 week)
Study: 13129449
Drug: Sun-dried raisins
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sun-dried raisins (120 g/d)
Study: 13129449
Drug: Cream of
Normalized name: Nubasics Soup Cream of Chicken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream of tartar (5 g/d)
Study: 10567179
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol (50 microg/d) and norethisterone acetate (2.5 mg/d, orally)
Study: 8896141
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for depression prevention, specific details not provided.
Study: 2061443
Drug: Ro 14‐9706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 14‐9706 (0.05% cream) applied twice daily for 16 weeks
Study: 2061443
Drug: Tretinoin (0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin (0.05% cream) applied twice daily for 16 weeks
Study: 25636235
Drug: vodka/orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: vodka/orange juice (20 g alcohol)
Study: 18957387
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg and Atenolol 50 mg (combination)
Study: 11742270
Drug: Cetirizine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (0.25 mg/kg body weight administered twice daily)
Study: 3321892
Drug: lidocaine/prilocaine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine/prilocaine mixture (5 g applied 90 min before testing)
Study: 29542045
Drug: Short-pulse PASCAL-PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-pulse PASCAL-PRP treatment (SP)
Study: 29542045
Drug: Conventional PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PRP treatment (TP)
Study: 19779715
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 + IFN (arm A, suspension)
Study: 19779715
Drug: Chronic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic maintenance of low-dose IL-2 + IFN (arm B, maintenance)
Study: 19779715
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after first progression
Study: 21352119
Drug: Brief ED‐MHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief ED‐MHL intervention (information about efficacious treatments, reputable self‐help books, and further information/services)
Study: 16244021
Drug: Saline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV (3 mL)
Study: 11857606
Drug: SRP/L (scaling/root
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP/L (scaling/root planing combined with laser application)
Study: 11857606
Drug: L (laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: L (laser application)
Study: 11857606
Drug: OHI (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI (oral hygiene instructions)
Study: 7538285
Drug: Iloprost (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (50-150 micrograms orally administered twice a day for 10 days)
Study: 2184994
Drug: Caffeine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3.5 mg/kg
Study: 2184994
Drug: Caffeine 7
Normalized name: caffeine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 7 mg/kg
Study: 31154565
Drug: Steroid-containing mouthwash
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-containing mouthwash
Study: 15129391
Drug: Intramuscular NMES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular NMES
Study: 3193518
Drug: X-ray preparation
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: X-ray preparation
Study: 24147543
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid photodynamic therapy (PDT)
Study: 24147543
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (PDT + imiquimod)
Study: 24147543
Drug: PDT or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT or imiquimod therapy (second course)
Study: 18771636
Drug: 2-day famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-day famciclovir (500 mg statim, then 250 mg twice daily)
Study: 18771636
Drug: 5-day famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day famciclovir (125 mg twice daily)
Study: 8129555
Drug: Myoglobin (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoglobin (MG)
Study: 2985353
Drug: Low bulk
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low bulk dietary supplement
Study: 2985353
Drug: High bulk
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bulk dietary supplement
Study: 29099344
Drug: Tezacaftor (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezacaftor (100 mg once daily) and Ivacaftor (150 mg twice daily)
Study: 26352221
Drug: ADAPT (Acceptance-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADAPT (Acceptance-based depression and psychosis therapy) for 4 months of outpatient treatment
Study: 26352221
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment as usual plus enhanced assessment and monitoring
Study: 18562411
Drug: Amisulpride therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride therapy
Study: 17596167
Drug: becocalcidiol 75
Normalized name: Becocalcidiol
DrugBank: Becocalcidiol (DB04891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: becocalcidiol 75 microg g(‐1) twice daily for 8 weeks
Study: 17596167
Drug: becocalcidiol 75
Normalized name: Becocalcidiol
DrugBank: Becocalcidiol (DB04891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: becocalcidiol 75 microg g(‐1) once daily for 8 weeks
Study: 14525752
Drug: Test Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Group (TG) - students directed to see patients with specific chief complaints (CC): orthopedic injury (OR), asthma exacerbation (AE), acute coronary syndrome (ACS), traumatic injury (TR), laceration (LAC), diabetic ketoacidosis (DKA).
Study: 10461500
Drug: Aggressive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive local therapy (surgery or radiosurgery)
Study: 8877267
Drug: Coronary Artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary Artery Bypass Grafting‐Patch Trial (CABG‐Patch)
Study: 6604723
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mezlocillin intramuscularly
Study: 6604723
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mezlocillin intramuscularly
Study: 4024002
Drug: Oral high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high frequency oscillation (RMS input pressure 1.2 cm H2O, mean pressure zero) applied for 30 minutes alternating with 30 minutes of rest
Study: 4024002
Drug: Oral high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high frequency oscillation
Study: 20538225
Drug: Frequency specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency specific microcurrent therapy (20 min stimulation)
Study: 20538225
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (control leg)
Study: 15705367
Drug: rLH supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH supplementation (both doses)
Study: 12559647
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody treatment for cytomegalovirus retinitis
Study: 11789259
Drug: Shoutai Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shoutai Pill
Study: 8997929
Drug: Treatment Counseling
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Counseling (TC)
Study: 29501977
Drug: Panitumumab with
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab with standard epirubicin, cisplatin, capecitabine (ECX) chemotherapy
Study: 29501977
Drug: Standard epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard epirubicin, cisplatin, capecitabine (ECX) chemotherapy without panitumumab
Study: 19430064
Drug: Silicon gel
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon gel sheeting applied to nares (Group 2, n=92)
Study: 19430064
Drug: No silicon
Approvals — FDA: no, EMA: no, PMDA: no
Description: No silicon gel applied to nares (Group 1, n=87)
Study: 18555936
Drug: Zidovudine 100
Normalized name: zidovudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 100 mg (test formulation)
Study: 18555936
Drug: Zidovudine 100
Normalized name: zidovudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 100 mg (reference formulation)
Study: 10321112
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (diuretics or beta-blockers)
Study: 1748257
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy in obese subjects
Study: 7201759
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of undiluted erythrocytes
Study: 7201759
Drug: Dilution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilution of packed erythrocytes with at least 100 ml of normal saline
Study: 26170351
Drug: Pregabalin 0
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 0 mg
Study: 24357936
Drug: GSK2190915 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 10 mg
Study: 24357936
Drug: GSK2190915 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 50 mg
Study: 19620846
Drug: Modafinil 100-mg
Normalized name: modafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 100-mg capsule BID
Study: 8417634
Drug: Glipizide 10
Normalized name: glipizide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 10 mg
Study: 8320055
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1 g/day for 28 days)
Study: 8320055
Drug: Alpha-tocopherol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (1 g/day for 28 days)
Study: 8320055
Drug: Alpha-tocopherol and
Normalized name: Alpha-tocopherol and selenium only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol and ascorbic acid (1 g/day for 28 days each)
Study: 21181560
Drug: Video-intervention (8-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-intervention (8-minute video depicting clinician expert and patients discussing challenges in seeking treatment for sickle cell pain)
Study: 19720914
Drug: Extra boost
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra boost dose of 16 Gy
Study: 17315077
Drug: Bifidobacterium lactis
Normalized name: bifidobacterium lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium lactis HN019 (high dose: 5 x 10^9 CFU/day)
Study: 17315077
Drug: Bifidobacterium lactis
Normalized name: bifidobacterium lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium lactis HN019 (medium dose: 1.0 x 10^9 CFU/day)
Study: 17315077
Drug: Bifidobacterium lactis
Normalized name: bifidobacterium lactis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium lactis HN019 (low dose: 6.5 x 10^7 CFU/day)
Study: 17315077
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no probiotic supplement)
Study: 11690570
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of at least 1000 mg per day
Study: 11690570
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of less than 1000 mg per day
Study: 9399717
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily physical activities (Group 1, 54 patients)
Study: 320112
Drug: Duogastrone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duogastrone (50 mg capsules, 200 mg daily for 12 weeks)
Study: 31494973
Drug: Picosecond alexandrite
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond alexandrite laser treatment (3 sessions at 4-week intervals)
Study: 31494973
Drug: Picosecond alexandrite
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond alexandrite laser treatment (5 sessions at 4-week intervals)
Study: 31494973
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (TCC) daily for at least 8 weeks
Study: 31494973
Drug: Picosecond alexandrite
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond alexandrite laser treatment (3 sessions)
Study: 31494973
Drug: Picosecond alexandrite
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond alexandrite laser treatment (5 sessions)
Study: 28486907
Drug: Crocin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (15 mg twice a day)
Study: 19029421
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (androgen deprivation)
Study: 16774150
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (0.3 mg)
Study: 16774150
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (5.0 mg)
Study: 10963173
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment without an insole (group II)
Study: 9205160
Drug: alpha-ketoglutarate (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-ketoglutarate (28 g added to blood cardioplegia)
Study: 7959497
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (1,000 mg daily for six days)
Study: 2455180
Drug: Clonidine treatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine treatment (150 micrograms t.i.d. for 2 weeks)
Study: 2455180
Drug: Clonidine treatment
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine treatment (0.36 ± 0.07 mg daily for 1 month)
Study: 2455180
Drug: Propranolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol treatment (160 mg daily for 1 month)
Study: 24047757
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lutein/d (n=48)
Study: 24047757
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lutein/d + 20 mg lycopene/d (n=48)
Study: 23868654
Drug: Liposomal local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal local therapy (LipoSaliva®, LipoNasal®, and Tears Again®) for 2 months
Study: 20642248
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) at 1 of 3 dose levels (5, 10, or 20 microg/b)
Study: 20642248
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal system (TDS)
Study: 18828707
Drug: Selective cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective cerebral hypothermia methods (e.g., surface cooling, intranasal selective hypothermia, transarterial or transvenous endovascular cooling, extraluminal vascular cooling, epidural cerebral cooling)
Study: 16627891
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and 2.4 g AA/kg/d
Study: 12841468
Drug: Interviewer-administered assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered assessment (participants' responses recorded by interviewer)
Study: 29028377
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% minoxidil (1 ml twice daily)
Study: 29028377
Drug: Local electrodynamic
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local electrodynamic microneedle treatments
Study: 29028377
Drug: Local electrodynamic
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local electrodynamic microneedle treatments plus topical 5% minoxidil (2 ml during each microneedle treatment)
Study: 20819623
Drug: Salmeterol/fluticasone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone (50 microg salmeterol and 500 microg fluticasone twice daily)
Study: 20819623
Drug: Ipratropium/albuterol (206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium/albuterol (206 microg albuterol and 36 microg ipratropium q.i.d)
Study: 19128289
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits by mental health nurses (4 weekly visits)
Study: 17162329
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g soy protein
Study: 17162329
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g soy protein
Study: 24203262
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol (0.5 mg/kg)
Study: 24203262
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (10 mg, 20 mg, 80 mg)
Study: 21162458
Drug: Mid-low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mid-low dose of alcohol (0.3 g/kg)
Study: 21162458
Drug: Alcohol doses
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol doses less than 0.5 g/kg
Study: 17982232
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once daily plus Budesonide 200 microg twice daily
Study: 15891595
Drug: One-point blood
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-point blood sampling at 12 min after Na18F injection
Study: 15891595
Drug: Venous blood
Normalized name: Venous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous blood sampling at 30 min after Na18F injection
Study: 7657418
Drug: Albuterol (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (360 micrograms total, 90 micrograms per dose, 4 metered doses)
Study: 31375606
Drug: Levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole 2.5 mg/kg alternate day
Study: 25350782
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (50,000 IU of cholecalciferol weekly for 8 weeks)
Study: 15566933
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg every 8 hours for </=3 doses
Study: 15566933
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg every 8 hours for </=3 doses
Study: 12089976
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of scaling and metronidazole gel
Study: 9066835
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray (220 micrograms/day)
Study: 9066835
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray (110 micrograms/day, dose reduction allowed)